000307465 001__ 307465
000307465 005__ 20251231120305.0
000307465 0247_ $$2doi$$a10.1053/j.semnuclmed.2025.11.022
000307465 0247_ $$2pmid$$apmid:41455672
000307465 0247_ $$2ISSN$$a0001-2998
000307465 0247_ $$2ISSN$$a1558-4623
000307465 037__ $$aDKFZ-2025-03064
000307465 041__ $$aEnglish
000307465 082__ $$a610
000307465 1001_ $$aSiegmund, Sophie C$$b0
000307465 245__ $$aCurrent status of FAP therapy in solid tumors.
000307465 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2025
000307465 3367_ $$2DRIVER$$aarticle
000307465 3367_ $$2DataCite$$aOutput Types/Journal article
000307465 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767095746_1386402$$xReview Article
000307465 3367_ $$2BibTeX$$aARTICLE
000307465 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307465 3367_ $$00$$2EndNote$$aJournal Article
000307465 500__ $$aepub
000307465 520__ $$aFAP-ligands as novel cancer radiopharmaceuticals in nuclear medicine have been recently translated successfully into the clinical space. Particularly small molecules (i.e. FAPI-46, FAPI-74) and peptides (i.e. FAP-2286, DOTAGA.SA.FAPi) seem to be some of the most promising molecular probes for imaging and therapy. Back in 2019, there have been slight reservations about adopting this new imaging probe, after the decades of the solidly established role of FDG PET/CT in oncological imaging. At that time, it was expected that these novel ligands might challenge Onco-PET as new cornerstones in the individualized tumor staging and even beyond. However, FAP-targeted imaging is today not intended to replace FDG PET/CT, but rather to complement cancer imaging and therapy, where cancer subtypes exhibit low glucose metabolism which often leads to moderate or very insufficient FDG uptake. Recently, numerous FAP-imaging studies -ranging from single-case reports to larger patient cohorts and even prospective trials have reinforced the empirical understanding of FAP-imaging as a potentially 'disruptive' modality compared to FDG PET/CT. The broader application of FAPI PET/CT has gained momentum, shaping a new narrative in oncological imaging and beyond. FAPI PET/CT is now increasingly recognized as a novel imaging agent that does not aim to replace FDG PET/CT, but rather supports it by enhancing diagnostic accuracy in specific sub-cohort of tumor entities, where FDG PET/CT tends to underperform. Several FAP-derivates- such as FAPI-04, FAPI-46, FAPI-74 for PET imaging as well as FAPI-34 for SPECT imaging were rapidly introduced into clinical practice. To date, FAP-imaging agents have steadily paved their way into clinical practice, particularly in tumor entities such as pancreatic ductal adenocarcinoma, gastroesophageal cancers, and hepatocellular carcinoma. Even in lung cancer, where FDG PET/CT has long held a well-established and clinically robust role, FAPI PET/CT has quickly emerged as a strong competitor, especially in case of lung adenocarcinoma. FAPI PET/CT has been gaining increasing acceptance beyond academic and scientific field as a tool for improved oncological imaging, while FAP theranostics is still in the elaboration and early translation. In contrast to imaging probes, FAP-derivates for therapy require a rather long residence (>48 h) time following successful target-binding at the cancer-associated fibroblast or FAP-positive tumor cells to enable the radiotoxic effect (beta- and alpha-emitter) and deliver enough LET to the cancer microenvironment. Meanwhile, FAP-based imaging probes are advancing into the clinical application, with Phase-II/III clinical trials expected as early as Q4/2025 (NCT07217704 & NCT07217717). In contrast, FAP-targeted therapeutics remain in the Phase-I or proof-of-concept stage but brings hope for patients with systemic disease who are left out and urgently need additional innovation drives beyond the standard care. This review article will give insight into the most recent developments in the FAP-Therapeutic applications of cancer treatments using several different promising FAP-derivates to improve FAP-theranostic in oncology.
000307465 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000307465 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307465 650_7 $$2Other$$a(177)Lu
000307465 650_7 $$2Other$$aCancer-associated fibroblasts
000307465 650_7 $$2Other$$aFAPI
000307465 650_7 $$2Other$$aFibroblast activation protein
000307465 650_7 $$2Other$$aRadioligand therapy
000307465 650_7 $$2Other$$aSolid tumors
000307465 650_7 $$2Other$$aTheranostics
000307465 7001_ $$aNovruzov, Emil$$b1
000307465 7001_ $$aMamlins, Eduards$$b2
000307465 7001_ $$aMori, Yuriko$$b3
000307465 7001_ $$aOtto, Sven$$b4
000307465 7001_ $$aCanis, Martin$$b5
000307465 7001_ $$aWatabe, Tadashi$$b6
000307465 7001_ $$aBaum, Richard P$$b7
000307465 7001_ $$0P:(DE-HGF)0$$aWerner, Rudolf A$$b8
000307465 7001_ $$aGiesel, Frederik L$$b9
000307465 773__ $$0PERI:(DE-600)2133379-8$$a10.1053/j.semnuclmed.2025.11.022$$gp. S0001299825001771$$pnn$$tSeminars in nuclear medicine$$vnn$$x0001-2998$$y2025
000307465 909CO $$ooai:inrepo02.dkfz.de:307465$$pVDB
000307465 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000307465 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000307465 9141_ $$y2025
000307465 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-27$$wger
000307465 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSEMIN NUCL MED : 2022$$d2024-12-27
000307465 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-27
000307465 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000307465 980__ $$ajournal
000307465 980__ $$aVDB
000307465 980__ $$aI:(DE-He78)MU01-20160331
000307465 980__ $$aUNRESTRICTED